Literature DB >> 10473254

Amphetamine acts within the medial basal forebrain to initiate and maintain alert waking.

C W Berridge1, J O'Neil, K Wifler.   

Abstract

Amphetamine-like stimulants exert well-known arousal-enhancing actions. Surprisingly, little is known concerning the neuroanatomical substrates through which these drugs enhance arousal. Previous work implicates a number of basal forebrain structures in the regulation of behavioral state. The current studies examined the effects of amphetamine infusions made directly within basal forebrain sites on behavioral, electroencephalographic, and electromyographic indices of arousal in anesthetized and unanesthetized rat. In the anesthetized rat, amphetamine elicited prolonged epochs of bilateral electroencephalographic activation when infused unilaterally (3.75 microg/150 nl) into an extended region of the medial basal forebrain, demarcated anteriorally by the anterior portion of the medial septal area (which includes posterior accumbens shell) and posteriorally by the posterior aspect of the preoptic area of the hypothalamus. In the unanesthetized (undisturbed, resting) rat, amphetamine infusions into this region elicited prolonged epochs of alert waking, which at the lowest dose (3.75 microg), qualitatively resembled normal waking. Infusions placed lateral (including within the substantia innominata), anterior (including within the core subregion of the nucleus accumbens), posterior, or dorsal to these structures, as well as directly within the lateral ventricles did not alter electroencephalographic or behavioral measures. These results indicate that a region of the medial basal forebrain, extending from the anterior medial septum/accumbens shell to the posterior preoptic area, is a site within which amphetamine-like stimulants act to enhance behavioral and electroencephalographic measures of arousal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473254     DOI: 10.1016/s0306-4522(99)00271-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

1.  Effects of d-amphetamine on simulated driving performance before and after sleep deprivation.

Authors:  Magnus Hjälmdahl; Anna Vadeby; Asa Forsman; Carina Fors; Gunnel Ceder; Per Woxler; Robert Kronstrand
Journal:  Psychopharmacology (Berl)       Date:  2012-05-26       Impact factor: 4.530

2.  Sleepiness and Unintended Sleep in Parkinson's Disease.

Authors:  David B. Rye
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 3.  Noradrenergic modulation of wakefulness/arousal.

Authors:  Craig W Berridge; Brooke E Schmeichel; Rodrigo A España
Journal:  Sleep Med Rev       Date:  2012-01-31       Impact factor: 11.609

Review 4.  Norepinephrine at the nexus of arousal, motivation and relapse.

Authors:  Rodrigo A España; Brooke E Schmeichel; Craig W Berridge
Journal:  Brain Res       Date:  2016-01-07       Impact factor: 3.252

5.  Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG.

Authors:  Florian Chapotot; Ross Pigeau; Frédéric Canini; Lionel Bourdon; Alain Buguet
Journal:  Psychopharmacology (Berl)       Date:  2003-01-28       Impact factor: 4.530

Review 6.  Narcolepsy in the older adult: epidemiology, diagnosis and management.

Authors:  Sangeeta S Chakravorty; David B Rye
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Amphetamine acts within the lateral hypothalamic area to elicit affectively neutral arousal and reinstate drug-seeking.

Authors:  Brooke E Schmeichel; Craig W Berridge
Journal:  Int J Neuropsychopharmacol       Date:  2013-07-29       Impact factor: 5.176

Review 8.  Noradrenergic modulation of arousal.

Authors:  Craig W Berridge
Journal:  Brain Res Rev       Date:  2007-12-04

Review 9.  Excessive daytime sleepiness and unintended sleep in Parkinson's disease.

Authors:  David B Rye
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

10.  A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.

Authors:  Brooke E Schmeichel; Frank P Zemlan; Craig W Berridge
Journal:  Neuropharmacology       Date:  2012-07-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.